4.1.1.53: phenylalanine decarboxylase

This is an abbreviated version!
For detailed information about phenylalanine decarboxylase, go to the full flat file.

Word Map on EC 4.1.1.53

Reaction

L-phenylalanine
=
Phenylethylamine
+
CO2

Synonyms

More, Aromatic L-amino acid decarboxylase, AADC, Decarboxylase, phenylalanine, L-Phenylalanine decarboxylase, PDC, PDC2, PDC1, L-tyrosine/L-phenylalanine decarboxylase, disA, phenylalanine decarboxylase 1, amino acid decarboxylase, phenylalanine decarboxylase 2

ECTree

     4 Lyases
         4.1 Carbon-carbon lyases
             4.1.1 Carboxy-lyases
                4.1.1.53 phenylalanine decarboxylase

Disease

Disease on EC 4.1.1.53 - phenylalanine decarboxylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Ataxia
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials.
Carcinogenesis
Glycine decarboxylase is an unusual amino acid decarboxylase involved in tumorigenesis.
Carcinoid Tumor
[Amino acid decarboxylase in pheochromocytoma and carcinoid tissue.]
Cerebral Palsy
Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
Dyskinesias
[Serum dopamine-beta-hydroxylase, glutamic acid decarboxylase and 1-aromatic amino acid decarboxylase in involuntary movement disorders (author's transl)]
Dystonia
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials.
Syndromic intellectual disability: A new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant.
Huntington Disease
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials.
Hypotension, Orthostatic
L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
Hypothyroidism
TSH and prolactin stimulation by the decarboxylase inhibitor benserazide in primary hypothyroidism.
Lung Neoplasms
Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype.
Migraine Disorders
A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach.
Movement Disorders
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials.
[Serum dopamine-beta-hydroxylase, glutamic acid decarboxylase and 1-aromatic amino acid decarboxylase in involuntary movement disorders (author's transl)]
Multiple System Atrophy
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials.
Muscle Hypotonia
Syndromic intellectual disability: A new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant.
Myoclonus
Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
Neoplasms
Characterization of neuroblastic tumors using 18F-FDOPA PET.
Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype.
Fluorescence and electron microscopic histochemistry of endocrine-like cells in gastric mucosa and argyrophil tumor of Praomys (Mastomys) natalensis. Analysis of 5-hydroxytryptamine, histamine, Histidine decarboxylase, and aromatic amino acid decarboxylase.
Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase.
Neuroendocrine Tumors
Characterization of neuroblastic tumors using 18F-FDOPA PET.
The effects of molar activity on [18F]FDOPA uptake in patients with neuroendocrine tumors.
Neurologic Manifestations
Syndromic intellectual disability: A new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant.
Paralysis
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials.
Parkinson Disease
Cheminformatics and virtual screening studies of COMT inhibitors as potential Parkinson's disease therapeutics.
Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers.
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials.
Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
phenylalanine decarboxylase deficiency
Corrigendum to "Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook" [Mol Genet Metab. 2019 May;127(1):12-22].
Pheochromocytoma
Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase.
[Amino acid decarboxylase in pheochromocytoma and carcinoid tissue.]
Small Cell Lung Carcinoma
Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype.
Supranuclear Palsy, Progressive
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials.
Tremor
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials.
Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
tryptophan 5-monooxygenase deficiency
Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters.